Cargando…

Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses

Although replication-defective human adenovirus type 5 (Ad5) vectors that express in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziraldo, Micaela, Bidart, Juan E., Prato, Cecilia A., Tribulatti, María V., Zamorano, Patricia, Mattion, Nora, D’Antuono, Alejandra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672010/
https://www.ncbi.nlm.nih.gov/pubmed/33250878
http://dx.doi.org/10.3389/fmicb.2020.591019
_version_ 1783611038990598144
author Ziraldo, Micaela
Bidart, Juan E.
Prato, Cecilia A.
Tribulatti, María V.
Zamorano, Patricia
Mattion, Nora
D’Antuono, Alejandra L.
author_facet Ziraldo, Micaela
Bidart, Juan E.
Prato, Cecilia A.
Tribulatti, María V.
Zamorano, Patricia
Mattion, Nora
D’Antuono, Alejandra L.
author_sort Ziraldo, Micaela
collection PubMed
description Although replication-defective human adenovirus type 5 (Ad5) vectors that express in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the present study, an optimization of the Ad5 system was explored and was proven to enhance the expression of FMDV capsid proteins and their association into virus-like particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[P(VP2)](OP)) which harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome, and drives the expression of the FMDV sequences from an optimized cytomegalovirus (CMV) enhancer-promoter as well. The Ad5[P(VP2)](OP) vaccine candidate also contains the amino acid substitutions S93F/Y98F in the VP2 protein coding sequence, predicted to stabilize FMD virus particles. Cells infected with the optimized vector showed an ∼14-fold increase in protein expression as compared to cells infected with an unmodified Ad5 vector tested in previous works. Furthermore, amino acid substitutions in VP2 protein allowed the assembly of FMDV O1/Campos/Brazil/58 VLPs. Evaluation of several serological parameters in inoculated mice with the optimized Ad5[P(VP2)](OP) candidate revealed an enhanced vaccine performance, characterized by significant higher titers of neutralizing antibodies, as compared to our previous unmodified Ad5 vector. Moreover, 94% of the mice vaccinated with the Ad5[P(VP2)](OP) candidate were protected from homologous challenge. These results indicate that both the optimized protein expression and the stabilization of the in situ generated VLPs improved the performance of Ad5-vectored vaccines against the FMDV O1/Campos/Brazil/58 strain and open optimistic expectations to be tested in target animals.
format Online
Article
Text
id pubmed-7672010
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76720102020-11-26 Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses Ziraldo, Micaela Bidart, Juan E. Prato, Cecilia A. Tribulatti, María V. Zamorano, Patricia Mattion, Nora D’Antuono, Alejandra L. Front Microbiol Microbiology Although replication-defective human adenovirus type 5 (Ad5) vectors that express in situ the capsid-encoding region of foot-and-mouth disease virus (FMDV) have been proven to be effective as vaccines in relevant species for several viral strains, the same result was not consistently achieved for the O1/Campos/Brazil/58 strain. In the present study, an optimization of the Ad5 system was explored and was proven to enhance the expression of FMDV capsid proteins and their association into virus-like particles (VLPs). Particularly, we engineered a novel Ad5 vector (Ad5[P(VP2)](OP)) which harbors the foreign transcription unit in a leftward orientation relative to the Ad5 genome, and drives the expression of the FMDV sequences from an optimized cytomegalovirus (CMV) enhancer-promoter as well. The Ad5[P(VP2)](OP) vaccine candidate also contains the amino acid substitutions S93F/Y98F in the VP2 protein coding sequence, predicted to stabilize FMD virus particles. Cells infected with the optimized vector showed an ∼14-fold increase in protein expression as compared to cells infected with an unmodified Ad5 vector tested in previous works. Furthermore, amino acid substitutions in VP2 protein allowed the assembly of FMDV O1/Campos/Brazil/58 VLPs. Evaluation of several serological parameters in inoculated mice with the optimized Ad5[P(VP2)](OP) candidate revealed an enhanced vaccine performance, characterized by significant higher titers of neutralizing antibodies, as compared to our previous unmodified Ad5 vector. Moreover, 94% of the mice vaccinated with the Ad5[P(VP2)](OP) candidate were protected from homologous challenge. These results indicate that both the optimized protein expression and the stabilization of the in situ generated VLPs improved the performance of Ad5-vectored vaccines against the FMDV O1/Campos/Brazil/58 strain and open optimistic expectations to be tested in target animals. Frontiers Media S.A. 2020-11-04 /pmc/articles/PMC7672010/ /pubmed/33250878 http://dx.doi.org/10.3389/fmicb.2020.591019 Text en Copyright © 2020 Ziraldo, Bidart, Prato, Tribulatti, Zamorano, Mattion and D’Antuono. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Ziraldo, Micaela
Bidart, Juan E.
Prato, Cecilia A.
Tribulatti, María V.
Zamorano, Patricia
Mattion, Nora
D’Antuono, Alejandra L.
Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title_full Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title_fullStr Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title_full_unstemmed Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title_short Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
title_sort optimized adenoviral vector that enhances the assembly of fmdv o1 virus-like particles in situ increases its potential as vaccine for serotype o viruses
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672010/
https://www.ncbi.nlm.nih.gov/pubmed/33250878
http://dx.doi.org/10.3389/fmicb.2020.591019
work_keys_str_mv AT ziraldomicaela optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT bidartjuane optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT pratoceciliaa optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT tribulattimariav optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT zamoranopatricia optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT mattionnora optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses
AT dantuonoalejandral optimizedadenoviralvectorthatenhancestheassemblyoffmdvo1viruslikeparticlesinsituincreasesitspotentialasvaccineforserotypeoviruses